A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer
Abstract
Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 6 subjects at WCMC. An additional 38 subjects enrolled (29 treated) at participating sub-sites. Reports submitted to WCMC DSMB in December 2014 with approval to proceed without modifications.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2015
- Accession Number
- ADA623383
Entities
People
- Scott T Tagawa
Organizations
- Cornell University